海量图书期刊资源,随时随地畅享阅读乐趣
The Future of Therapy for Relapsed/Refractory Multiple Myeloma: Emerging Agents and Novel Treatment StrategiesPhilippe Moreau · 2012
Managing multiple myeloma: the emerging role of novel therapies and adapting combination treatment for higher risk settingsPaul G. Richardson; Jacob Laubach; Constantine S. Mitsiades; Robert Schlossman; Teru Hideshima; Katherine Redman; Dharminder Chauhan; Irene M. Ghobrial; Nikhil Munshi; Kenneth C. Anderson · 2011
Systemic Management for Advanced Hepatocellular Carcinoma: A Review of the Molecular Pathways of Carcinogenesis, Current and Emerging Therapies, and Novel Treatment StrategiesSaffo, Saad; Taddei, Tamar H. · Digestive Diseases and Sciences · 2019
Targets and Emerging Therapies for Schizophrenia (Albert/Pharmacological Schizophrenia) || Metabotropic Glutamate 2/3 Receptor Agonists and Positive Allosteric Modulators of Metabotropic Glutamate Receptor 2 as Novel Agents for the Treatment of SchizophreniaAlbert, Jeffrey S.; Wood, Michael W. · 2012
Advances in the Management of MyelofibrosisKomrokji, Rami S.; Verstovsek, Srdan; Padron, Eric; List, Alan F. · Cancer Control · 2012
A comprehensive review of pacritinib in myelofibrosisVerstovsek, Srdan; Komrokji, Rami S · Future Oncology · 2015
Ruxolitinib dose management as a key to long-term treatment successMesa, Ruben A.; Komrokji, Rami S.; Verstovsek, Srdan · International Journal of Hematology · 2016
Myeloid/lymphoid neoplasms with <i>FGFR1</i> rearrangementStrati, Paolo; Tang, Guilin; Duose, Dzifa Y.; Mallampati, Saradhi; Luthra, Rajyalakshmi; Patel, Keyur P.; Hussaini, Mohammad; Mirza, Abu-Sayeef; Komrokji, Rami S.; Oh, Stephen; Mascarenhas, John; Najfeld, Vesna; Subbiah, Vivek; Kantarjian, Hagop; Garcia-Manero, Guillermo; Verstovsek, Srdan; Daver, Naval · Leukemia & Lymphoma · 2017
Practical Measures of Clinical Benefit With Ruxolitinib Therapy: An Exploratory Analysis of COMFORT-IMiller, Carole B.; Komrokji, Rami S.; Mesa, Ruben A.; Sun, William; Montgomery, Michael; Verstovsek, Srdan · Clinical Lymphoma Myeloma and Leukemia · 2017
Mutational landscape of myelodysplastic/myeloproliferative neoplasm – unclassifiable (MDS/MPN-U)Bose, Prithviraj; Nazha, Aziz; Komrokji, Rami S.; Patel, Keyur P.; Pierce, Sherry A.; Al-Ali, Najla; Sochacki, Andrew; Shaver, Aaron; Ma, Wencai; Su, Xiaoping; Daver, Naval G.; DiNardo, Courtney D.; Garcia-Manero, Guillermo; Loghavi, Sanam; Bueso-Ramos, Carlos; Kantarjian, Hagop M.; Sekeres, Mikkael A.; Savona, Michael R.; Maciejewski, Jaroslaw P.; Verstovsek, Srdan · Blood · 2018
Immunomodulatory drugs in multiple myelomaAndhavarapu, Swati; Roy, Vivek · Expert Review of Hematology · 2013
Prognostic factors in Hodgkin lymphomaJosting, Andreas · Expert Review of Hematology · 2010
Iron (III) isomaltoside 1000Mace, Thomas AR; Syed, Ahsan; Bhandari, Sunil · Expert Review of Hematology · 2013
Hepcidin biology and therapeutic applicationsNemeth, Elizabeta · Expert Review of Hematology · 2010
Current status of thrombopoietic agentsRhodes, Elizabeth; Stasi, Roberto · Expert Review of Hematology · 2010
Heparin induced thrombocytopenia: reviewDasararaju, Radhika; Singh, Nirupama; Mehta, Amitkumar · Expert Review of Hematology · 2013
Clinical management of aplastic anemiaDeZern, Amy E; Brodsky, Robert A · Expert Review of Hematology · 2011
Clofarabine in leukemiaGhanem, Hady; Jabbour, Elias; Faderl, Stefan; Ghandhi, Varsha; Plunkett, William; Kantarjian, Hagop · Expert Review of Hematology · 2010